Abstract
Despite increasing rates of renal replacement therapy, data supporting the safe and effective use of HIV treatment guidelines preferred regimens in people on hemodialysis or peritoneal dialysis is limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a guideline recommended initial regimen for most people with HIV with FDA-approval for use in virologically suppressed people receiving chronic hemodialysis; however, the safety and efficacy of BIC/FTC/TAF remains unknown when used in patients on chronic ambulatory peritoneal dialysis (CAPD). We report the first case of BIC/FTC/TAF use in CAPD.
| Original language | English |
|---|---|
| Pages (from-to) | 139-141 |
| Number of pages | 3 |
| Journal | International Journal of STD and AIDS |
| Volume | 34 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2023 |
Bibliographical note
Publisher Copyright:© The Author(s) 2022.
ASJC Scopus Subject Areas
- Dermatology
- Public Health, Environmental and Occupational Health
- Pharmacology (medical)
- Infectious Diseases
Keywords
- AIDS
- antiretroviral therapy
- antiviral
- Human immunodeficiency virus viral disease
- treatment
- viral disease
Disciplines
- Dermatology
- Public Health
- Medical Pharmacology
- Infectious Disease
Fingerprint
Dive into the research topics of 'Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS